Kevin Ali, Organon CEO
December 13, 2024 03:53 PM EST
Pharma
FDA+

Organon's steroid-free cream Vta­ma wins ap­proval in atopic der­mati­tis

Nicole DeFeudis

Editor

Organon won a la­bel ex­pan­sion on Fri­day for the steroid-free top­i­cal cream it picked up from its Oc­to­ber ac­qui­si­tion of Der­ma­vant.

Vta­ma, al­so known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times